NASDAQ$LPCN
Lipocine Inc · Q3 2025 earnings
Q3 2025 earnings · · Before market open · Investor relations
Briefing
Lipocine reported Q3 2025 revenue of $0.5M with a net loss of $3.2M ($0.59 per share).
Revenue was minimal while the company advanced oral pipeline candidates. Net loss was $3.2 million, or $(0.59) per share, with R&D and G&A reflecting clinical-stage operations.
- Limited revenue quarter; focus on TLANDO and pipeline.
- Net loss $3.2M; EPS $(0.59).
- Cash runway and regulatory milestones are key catalysts.
- Operating spend aligned with development timelines.
Headline financials
Revenue & EPS history
Lipocine · Revenue · Quarterly
$115K
Forward guidance
The filing discusses Lipocine's outlook, capital priorities, and key risks, including guidance or operating targets where disclosed.
Tailwinds
- Lipocine cites execution and demand supporting the near-term outlook.
- Balance sheet and capital allocation remain focal points in the filing.
Headwinds
- GAAP profitability remained under pressure in the quarter.
- Macro, competition, and input costs may pressure margins quarter to quarter.
- One-time items and segment mix can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2025
+0.7%
Avg return
Earnings day
-2.6%
Avg return
5 days after
-3.6%
Avg return
30 days after
55%
28 / 51 earnings
Positive
+23.5%
Q3 2015
Best reaction
-22.9%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -1.6% | -4.1% | — | |
| Q4 2025 | +2.9% | -6.9% | -73.5% | |
| Q3 2025 | +3.1% | +12.9% | +23.0% | |
| Q2 2025 | +0.8% | -1.8% | -1.3% | |
| Q1 2025 | +7.0% | -2.9% | -16.5% | |
| Q4 2024 | -3.3% | -10.9% | -13.6% | |
| Q3 2024 | -21.5% | -15.8% | -15.8% | |
| Q2 2024 | -12.5% | -24.6% | -27.4% | |
| Q1 2024 | +9.7% | +10.3% | +55.1% | |
| Q4 2023 | +0.8% | +10.6% | +34.1% | |
| Q3 2023 | -6.0% | +10.3% | +1.7% | |
| Q2 2023 | -0.2% | -1.8% | -27.7% | |
| Q1 2023 | -4.6% | -21.9% | -4.9% | |
| Q4 2022 | -9.2% | -26.4% | -23.8% | |
| Q3 2022 | -3.2% | -2.8% | +3.6% | |
| Q2 2022 | -11.9% | -14.2% | -34.8% | |
| Q1 2022 | -6.2% | -4.1% | +13.6% | |
| Q4 2021 | +7.8% | +2.8% | -16.3% | |
| Q3 2021 | -0.8% | +0.8% | -5.9% | |
| Q2 2021 | +2.3% | +5.3% | -6.0% | |
| Q1 2021 | +0.0% | -1.4% | -12.2% | |
| Q4 2020 | +11.4% | +3.4% | +3.4% | |
| Q3 2020 | +4.9% | +1.4% | -4.9% | |
| Q2 2020 | -6.1% | +8.2% | -34.2% | |
| Q1 2020 | +6.2% | +18.2% | +44.0% | |
| Q4 2019 | -22.9% | -20.0% | +13.3% | |
| Q3 2019 | -14.5% | -50.8% | -56.0% | |
| Q2 2019 | +5.6% | +5.6% | +78.9% | |
| Q1 2019 | +1.6% | -3.2% | -19.9% | |
| Q4 2018 | +5.1% | +11.2% | +16.3% | |
| Q3 2018 | +8.7% | +6.7% | -7.3% | |
| Q2 2018 | +4.2% | +7.0% | +14.0% | |
| Q1 2018 | +15.6% | -28.6% | -19.5% | |
| Q4 2017 | -6.3% | -3.8% | +6.3% | |
| Q3 2017 | +2.3% | +3.9% | +0.6% | |
| Q2 2017 | +2.3% | -3.4% | -14.0% | |
| Q1 2017 | -4.1% | -12.0% | -14.2% | |
| Q4 2016 | -2.5% | +0.0% | -6.3% | |
| Q3 2016 | +13.0% | +15.6% | +16.9% | |
| Q2 2016 | +14.4% | +21.4% | -8.7% | |
| Q1 2016 | -4.9% | — | — | |
| Q4 2015 | +8.0% | — | — | |
| Q3 2015 | +23.5% | — | — | |
| Q2 2015 | +15.9% | — | — | |
| Q1 2015 | +5.0% | — | — | |
| Q4 2014 | -11.1% | — | — | |
| Q3 2014 | +14.4% | — | — | |
| Q2 2014 | -2.1% | — | — | |
| Q4 2013 | +5.4% | — | — | |
| Q1 2014 | +5.4% | — | — | |
| Q3 2013 | -17.5% | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2012 | — | — | — | |
| Q2 2012 | — | — | — | |
| Q1 2012 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro